Among the low-risk genetic subgroups, ETV6/RUNX1-Rearranged ALL represents approximately 20% of pediatric ALL cases and generally has a favorable outcome; it shares a gene expression profile and immunophenotype with ETV6/RUNX1-rearranged ALL but lacks the fusion gene, with genetic alterations including changes in ETV6, IKZF1, and TCF3, making outcomes appear less favorable compared to ETV6/RUNX1 fusion, necessitating careful monitoring and potentially more aggressive treatment strategies [28]. The gene discussed is TCF3; the disease is acute lymphoblastic leukemia.